

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

A YOUNG CHILD FORMULA SUPPLEMENTED WITH L. REUTERI AND GALACTO-OLIGOSACCHARIDES MODULATES THE COMPOSITION AND FUNCTION OF THE GUT MICROBIOME SUPPORTING BONE AND MUSCLE DEVELOPMENT IN TODDLERS

Nicolas Bonnet¹, Maria Rosario Capeding², Léa Siegwald¹, Marc Garcia-Garcera¹, Thibaut Desgeorges¹, Hanne L.P. Tytgat¹, Laura-Florina Krattinger³, Jowena Lebumfacil⁴, Loudhie Cyd Phee², Janne Marie Moll⁵, Alexander Gudjonsson⁵, Paula Rodriguez-Garcia⁵, Jerome N Feige¹, Ivana Jankovic⁶, Yipu Chen⁶, Delphine Egli⁶, Marie-Noëlle Horcajada¹

Affiliations:

1. Nestlé Institute of Health Sciences, Nestlé Research, Vers-Chez-Les-Blanc & EPFL innovation Park, Lausanne, Switzerland.
2. Clinical Research Unit, Asian Foundation for Tropical Medicine, Inc. (AFTMI), Muntinlupa City, Philippines
3. Clinical Research Unit, Nestlé Research, Lausanne, Switzerland
4. Wyeth Nutrition, Makati City, Philippines
5. Clinical Microbiomics, Copenhagen, Denmark.
6. Nestlé Product Technology Center – Nutrition, Société des Produits Nestlé S.A., Vevey, Switzerland

* Corresponding author: marienoelle.horcajada@rdls.nestle.com, Tel: +41 21 785 85 84.

40

41 Key Points (max 100W)

42 This section will be completed further

43 Abstract (max 350 words)

44 **Importance**

45 Toddlerhood is a key window of opportunity for development of musculoskeletal system and
46 microbiome. In this study we tested the efficacy of a synbiotic-based young child formula on
47 bone and muscle strength and microbiome maturation in young children during motor-skill
48 development.

49 **Intervention**

50 In this randomized, double-blind controlled trial, children aged 2-3 years received either an
51 experimental young child formula (EYCF) containing a combination of *Limosilactobacillus*
52 *reuteri* DSM 17938 and galacto-oligosaccharides (GOS) or a minimally fortified milk (CM)
53 for 6 months. A third arm remained on their habitual diet.

54 **Main outcomes and measures**

55 Bone quality (tibia speed of sound), muscle strength (handgrip), microbiota composition
56 (shotgun metagenomics) and functionality (fecal metabolome) were evaluated at baseline,
57 and after 3 months and 6 months of intervention. Microbiota and metabolomic features were
58 associated to each other and to clinical bone and muscle readouts at the same timepoints.

59 **Results**

60 Tibial speed of sound was significantly increased after 6 months (primary end point, $p < 0.01$)
61 and 3 months ($p < 0.05$) of EYCF vs CM feeding. These effects on bone strength were
62 paralleled by significantly higher muscle strength after 6 months in EYCF vs CM. The
63 intervention significantly remodeled microbiome composition, with enrichment of *L. reuteri*,
64 and higher bifidobacteria presence in the stools of EYCF vs CM children at both 3 and 6
65 months. Increased *L. reuteri* abundance after 6 months of EYCF consumption was associated
66 with higher bone quality and muscle strength. Stool metabolomics were significantly
67 modulated by EYCF consumption with 45 metabolites significantly modified and associated
68 to microbiome compositional changes such as *Bifidobacterium* spp. and *L. reuteri* expansion.
69 Pairing of metagenomic and metabolomic signatures induced by EYCF revealed an
70 enrichment of tryptophane and indole metabolism which significantly associated to bone and
71 muscle strength clinical outcomes.

72

73 **Conclusions and relevance**

74 Consumption of an experimental young child formula containing a *L. reuteri* + GOS
75 synbiotic improves musculoskeletal development in toddlers that was associated with a
76 modulation of microbiota composition and functionality. These results provide novel
77 mechanistic insights on gut-musculoskeletal crosstalk during early life and demonstrate that

78 nutritional interventions targeting the microbiome can support healthy bone and muscle
79 development and may contribute to functional motorskills acquisition during childhood.

80 **Trial registration**

81 The trial was registered at clinicaltrials.gov as NCT04799028

82

83 **Key words**

84 Bone, skeletal muscle, nutrition, early life growth, synbiotic, microbiome

85 Introduction

86 Bone is a “dynamic” and highly specialized connective tissue, providing mechanical
87 support for muscular activity and physical protection to tissues and internal organs, as well as
88 a repository for the systemic mineral homeostasis (1).

89 Bone tissue is constantly renewed in adults as well as in children and adolescents.
90 “Strong bones” are defined by two different aspects of bone geometry (length & width) and
91 by the amount of mineral deposited in the bone tissue. It is interesting to note that osteoblasts
92 first synthesize and excrete the bone matrix proteins (osteoids) which later on, at a short
93 distance from the bone-forming cells, mineralize until about 70% of the bone, with the
94 remaining 30% at longer distance (6-12 months later). Therefore, bone could rapidly be
95 under-mineralized if the mineralization rate is reduced compared to velocity growth (2).

96 Most data seem to confirm that an adequate intake of calcium is important in the
97 mineralization process to reach skeletal maturity. Prospective randomized clinical trials have
98 demonstrated that calcium supplementation may increase bone mass acquisition in children,
99 adolescence and adulthood up to the third decade of life (3, 4). When calcium
100 supplementation ceases, the beneficial effect on bone accretion seems to disappear (5-7).
101 Inadequate intake of calcium may contribute to failure to develop strong bones during early
102 life (5). Therefore, daily recommended calcium intakes have been established by various
103 authorities to meet the needs for growth and bone development in children (5). In addition,
104 nutrients (such as vitamin D) which help calcium incorporation into bone may also contribute
105 to bone development (5, 8).

106 Early life and toddlerhood are crucial windows for bone growth, but they are also
107 critical for microbiome development (9). The influence of the microbiome on bone
108 (re)modeling has been demonstrated through different mechanisms of action such as
109 modulation of mineral absorption, immune cell activity, and production of microbial

110 metabolites (10). Given the link between the microbiome functionality and bone
111 development, modulation of the gut microbiome by nutritional supplements has been
112 explored to provide novel strategies to maximize bone gain during childhood through the gut-
113 bone axis (11). Pre-clinical growth models documented an effect of the prebiotic GOS on
114 mineral absorption (12), on gut hormones known to impact bone metabolism (13, 14) and on
115 bone strength and mineral density (15-17). In a pre-clinical model of bone loss, a positive
116 effect of *Limosilactobacillus reuteri* (*L. reuteri*) ATCC PTA 6475 on trabecular bone
117 microarchitecture was reported (18) (19). We have shown previously *in vitro* that the
118 administration of a synbiotic consisting of pre-cultivated *L. reuteri* DSM 17938 and GOS
119 stimulate microbiome metabolite production, microbial engraftment and microbiome profiles
120 compared to *L. reuteri* DSM 17938 alone (20). In this study, we also confirmed the ability of
121 specific metabolites (e.g. short chain fatty acids (SCFAs), known to regulate bone
122 homeostasis *in vivo* (21), to improve osteoblastogenesis (20). The impact of the intervention
123 on muscle progenitor cells remained to be evaluated.

124 In clinical settings, GOS was shown to positively impact calcium absorption in
125 adolescents (22) and post-menopausal women (23). Additionally, formula containing a fat
126 blend with low levels of sn-1,3 long-chain saturated fatty acids (LCSFAs) positively
127 impacted calcium absorption in infants by decreasing calcium soaps formation (24-27).
128 Finally, one year of supplementation with *L. reuteri* ATCC PTA 6475 in post-menopausal
129 women reduced loss of tibia bone mineral density compared to placebo, suggesting that
130 probiotics are a novel candidate approach to prevent age-associated bone loss and
131 osteoporosis (20, 21, 28).

132 Skeletal muscle mass and strength drastically increase from birth to adulthood (29)
133 and is highly dependent on nutrition (30). Muscle mass and strength increase through muscle
134 fiber hypertrophy due to an increase of protein synthesis. The mechanism is driven by both an

135 increase in the myonuclear protein synthesis rate and muscle progenitor cell activity, which
136 insure myonuclear accretion. The role of muscle progenitor cells in muscle development is
137 important especially during the first years of life (31-34).

138 Another potential driver of muscle development is the gut microbiome, as more and more
139 studies underline the existence of a gut-muscle axis (35), similarly to growing evidence for
140 the gut-bone axis. It remains however unknown whether modulating the microbiome can
141 impact bone and muscle development in children.

142 In this current study we assessed the effect of an experimental young child formula (EYCF),
143 containing synbiotic blend of pre-cultivated *L. reuteri* DSM 17938 and GOS (4g/L), in
144 toddlers through a double-blind randomized controlled trial, compared to minimally fortified
145 milk (control milk, CM). The primary endpoint of this clinical study was tibia quality
146 (ultrasound) after 6 months of intervention. Evaluation of muscle force (handgrip) was also
147 performed. To evaluate the potential contribution of the microbiome on bone and muscle
148 development, the fecal microbiota composition and fecal metabolome were analyzed.
149 Additionally, we investigated the effects of product digestion of this experimental formula,
150 obtained via *in vitro* fermentation, on muscle progenitor cells activities.

151

152 Material & methods

153

154 *In vitro* experiments with human myoblasts

155 *In vitro* assays were performed on primary human skeletal muscle myoblasts (Lonza).
156 Myoblasts were seeded at 90-110 cells per mm² on well plates pre-coated with 20 µg/ml
157 human fibronectin. To evaluate the differentiation potential of myoblasts, cells were cultured
158 for 3 days in growth medium (SkM-M, AMSBIO) with the product generated after the *in*
159 *vitro* digestion of experimental blends (milk matrix+/- GOS+/- *L. reuteri*) as previously
160 described (20). To evaluate the myogenesis process, cells were cultured for 3 days in growth

161 medium (SkM-M, AMSBIO) followed by 3 days of culture in differentiation medium
162 (DMEM/F12, Horse serum 2%, Pen/Strep 1%). Cells were exposed to different treatments at
163 each step (6 days of treatment, range of fusion index in milk matrix control group is 46.46%
164 ± 3.832 (SD)). At the end of the treatment period, cells were fixed with PFA 4%,
165 permeabilized with Triton 0.5%, blocked with 4% Bovin Serum Albumin and stained for
166 Troponin T assay overnight at 4°C. The next day, the cells were washed and stained with
167 Hoechst 33342 (Sigma) and secondary antibodies coupled with fluorescent molecules
168 (ThermoFisher Scientific).

169 Image acquisition was performed with ImageXpress Micro confocal microscope (Molecular
170 devices) and image analysis was performed with MetaXpress Software to quantify the
171 myotube area and/or cell fusion index (myogenesis).

172

173 Study population

174 Healthy Filipino toddlers between 24 months (± 1 week) to 36 months (± 1 week) of age, not
175 consuming pre- or probiotics in the past month and without history of bone malabsorption,
176 metabolic, congenital, or chromosomal abnormalities were eligible for this trial.

177 Children who fulfilled all of the following inclusion criteria were included:

- 178 1. Written informed consent has been obtained from the parent(s)/legally acceptable
179 representative (LAR).
- 180 2. Singleton, full-term gestational birth (≥ 37 completed weeks of gestation), with a birth
181 weight of ≥ 2.5 kg and ≤ 4.5 kg.
- 182 3. Child is between 24 months ± 1 week to 36 months ± 1 week at inclusion.
- 183 4. Child is not currently consuming nor has consumed any formulas or taking any
184 supplements with pre- or probiotics at enrolment or in the past month.

185 5. Child's parent(s)/guardian is of legal age of consent, must understand the informed
186 consent and other study documents, and is willing and able to fulfill the requirements of the
187 study protocol.

188 Exclusion criteria, that rendered children ineligible for inclusion:

189 1. Chronic infectious, metabolic, genetic illness or other disease including any condition
190 that impacts feeding or growth.

191 2. History of bone malabsorption, metabolic, congenital, or chromosomal abnormality
192 known to affect feeding or growth.

193 3. Use of systemic antibiotics or anti-mycotic medication in the 4 weeks preceding
194 enrollment.

195 4. Known or suspected cows' milk protein intolerance / allergy, or lactose intolerance, or
196 severe food allergies that impact diet.

197 5. Current breast milk feeding in place of all other milk, and/or milk alternatives.

198 6. Clinical signs of severe micronutrient deficiencies.

199 7. Parent(s) not willing / not able to comply with the requirements of study protocol.

200 8. Child's participation in another interventional clinical trial.

201

202 Study design

203 The study is a randomized, controlled, double-blind intervention conducted in healthy male
204 and female children, which were exposed to either minimally fortified cow milk (CM) or to
205 experimental young child formula (EYCF). A non-randomized habitual diet reference group
206 was also included from enrollment to 6 months (REF). The study was conducted at the Asian
207 Hospital and Medical Center in Muntinlupa City, Philippines from June 2021 to August
208 2022. The Asian Hospital and Medical Center Research Ethics Committee approved the
209 study (REF:QF-REC-007). Written informed consent from all parents or legally acceptable

210 representatives was obtained prior to screening and enrolment. The trial was registered at
211 clinicaltrials.gov as NCT04799028.

212 Children completed three visits (enrollment, after 3 months, and after 6 months). Stool
213 samples were collected at all three visits. The primary endpoint was tibia bone mass index
214 measured by speed of sound (SOS) at 6 months of intervention. Secondary endpoints
215 included additional bone mass index parameters, muscle force (Handgrip strength)
216 gastrointestinal (GI) tolerance and stooling patterns, excretion of fecal calcium fatty acid
217 soaps, serum vitamin D, urine and blood bone turnover markers, gut microbiota, fecal
218 metabolism and safety endpoints including growth, medication use, and standard adverse
219 events (AEs). A schematic of the trial design is presented in Fig. 1A and 1B.

220

221 **Product allocation, product description, groups and timing**

222 Toddlers were randomly assigned to the control (CM) or experimental (EYCF) formula.
223 Children were fed the assigned formulas for 6 months from enrollment. The nutritional
224 composition of EYCF and CM are within regulatory limits for children's formula and
225 fortified milks, respectively.

226

227 • CM: Powdered cow's milk, fortified with the key nutrients (vitamins A, D, E, and C),
228 with nutritional composition all within regulatory limits and an average of nutrient levels
229 found in commonly consumed children's milk in Philippines (Department of Science and
230 Technology - Food and Nutrition Research Institute (DOST-FNRI). 2016. Philippine
231 Nutrition Facts and Figures 2015: Dietary Survey).

232

233 • EYCF: Powdered cow's milk-based toddler formula containing calcium (120 mg /
234 100 mL), Vitamin D (61IU/100 mL), GOS (4 g/L), pre-cultivated *L. reuteri* DSM 17938 (at

235 concentration that guarantees 10^8 cfu/day)) and fat blend low in sn-1, -3 Long-Chain
236 Saturated Fatty Acids (LCSFAs).

237 Since EYCF is a toddler formula tailored to the needs of young children, nutritional profile of
238 EYCF is slightly different from that found in CM, especially pertaining to protein levels. The
239 nutritional composition of the CM and EYCF is summarized in Supplementary table S1.

240 Children randomized to CM or EYCF received the feeding orally, ad libitum, every day for 6
241 months from enrollment. Recommended consumption in line with dietary guidelines was at
242 least 2 servings per day (~ 235mL of reconstituted product per serving). Children in the
243 reference group continued their habitual diet.

244

245 **Clinical readouts**

246 *Anthropometry*

247 Anthropometric parameters were collected at baseline and 6 months after intervention,
248 including weight (kg), height (cm) and head circumference (cm); BMI was calculated
249 (kg/m^2). Children were weighted without clothing or diaper on a calibrated electronic
250 weighing scale and measurements were recorded to the nearest gram. Height was measured
251 using a stadiometer to the nearest 0.1 cm. Head circumference was measured using a
252 pediatric non-elastic tape measure to the nearest 0.1 cm. All anthropometric measures were
253 repeated until reproduced within a pre-defined acceptable range (i.e. 10 grams for weight, 0.5
254 cm for height and 0.2 cm for head circumference). For the baseline and 6 months timepoint,
255 corresponding WHO child growth standard z-scores including weight-for-age, height-for-age,
256 head circumference-for-age and BMI-for-age were computed. Radius and tibia length were
257 determined using a rubber, as previously described (36).

258

259 *Speed of sound of the tibia and radius*

260 Speed of sound (SOS) readings were measured using the Sunlight Omnisense® 9000S Bone
261 Sonometer (BeamMed Ltd) as previously described (37, 38) at baseline, 3 and 6 months after
262 intervention. This device uses the axial transmission technique to measure the speed at which
263 ultrasound waves travel across the long axis of the bone surface (39). A handheld ultrasound
264 probe contains transmitting and receiving transducers. The probe emits an array of ultrasound
265 waves with a center frequency of 1.25 MHz. The signal travels through the soft tissues until it
266 encounters bone. The waves that encounter the bone at a “critical angle” (angle of incidence
267 that results in 90 degrees angle of refraction) are propagated along the surface of the long axis
268 of the bone, and then exit the bone at the same “critical angle” back into the soft tissue. The
269 first signal to be detected by the receiving transducers is used to calculate SOS in meters per
270 second (m/s). The device uses proprietary algorithms to account for differences in soft tissue
271 thickness, normalizing the SOS measurements for comparison to children of similar age. The
272 device is designed to measure SOS of bones that are close to the surface of the skin, such as
273 the tibia or radius. Ultrasound transmission gel (Aquasonic 100 Ultrasound Transmission
274 Gel; Parker Laboratories Inc.) was used to obtain good acoustic contact between the probe
275 surface and the soft tissue overlying the tibia.

276

277 *Muscle force as measured by Handgrip digital dynamometers*

278 Force was measured with the Jamar hand dynamometer at baseline and 6 months after the
279 intervention as previously described (40). The child was seated upright on a chair in front of
280 the instrument, which was placed on a table. The most used posture was as follows: shoulders
281 adducted and neutrally rotated, elbow flexed at 90°, forearm in neutral and wrist between 0
282 and 30° of dorsiflexion. The child grasped the handle and was allowed to become familiar
283 with the instrument by obtaining a good grip, squeezing lightly and watching the
284 corresponding increase in grip strength on the digital display. When ready, the child was

285 asked to squeeze as hard as possible for 10 s on a verbal “go” signal. Three trials for each
286 hand were conducted, alternating hands, and always starting with the dominant hand. There
287 was always a break of at least 1 min between the tests on the same hand. The results of each
288 of the three tests per hand were noted in a test protocol. Some systematic verbal instruction
289 was given like: ‘I want you to hold the handle like this and squeeze as hard as you can’. The
290 examiner demonstrated and then gave the dynamometer to the subject. After the child was
291 positioned appropriately, the examiner said, ‘Are you ready? Squeeze as hard as you can’. As
292 the child began to squeeze, the examiner said, ‘Harder!... Harder!... Relax’(41).

293

294 *Gastrointestinal tolerance and stooling patterns*

295 Gastrointestinal (GI) tolerance was assessed using the Toddler Gut Comfort Questionnaire
296 (TGCQ) at baseline, after 3 and 6 months of intervention. It consists of 10 questions
297 pertaining to GI-related symptoms and behaviors including constipation, diarrhea, gassiness,
298 abdominal pain, difficult to pass / hard stools, bloating, fussiness, and sleep problems that are
299 recalled retrospectively over the past week from a parent’s perspective. Possible scores for
300 each individual question on the TGCQ range from 1 (Never/None/Not a problem at all) to 6
301 (Always/Very strong). Scores for each of the 10 questions were summed to provide a total
302 score with a possible total score of 10 to 60. Stooling patterns, which includes stool
303 frequency and consistency were recorded via the GI symptom and Behavior Diary at
304 baseline, after 3 and 6 months of intervention. Stool consistency was rated by parents on a 5-
305 point stool scale: 1=watery, 2=runny, 3=mushy soft, 4=formed, and 5=hard.

306

307 **Blood markers**

308 Subject’s blood bone turnover marker levels including C-terminal cross-linked telopeptides
309 of type I collagen (CTX) and procollagen type I N-propeptide (P1NP) were measured at

310 baseline and 6 months after the intervention as described in (42). Bone turnover index define
311 as (CTX-PINP)/PINP was calculated as described in (42)

312

313 Blood vitamins

314 Sample preparation including calibration curves, quality controls (QC) and study samples,
315 was automated and performed on a Microlab Star M liquid handler (Hamilton, Reno, NV,
316 USA). Briefly, samples were thawed at room temperature, vortexed, and transferred to
317 polypropylene plates containing internal standards (IS) and Ascorbic Acid. Samples were
318 precipitated using 7.5% trichloroacetic acid (TCA), vortexed during 10min and finally
319 centrifuged at 2500 rpm for 10 minutes. Supernatant was transferred and filtered onto an
320 AcroPrep Advance 96 filter plate with a 0.2 μm membrane (Pall, Port Washington, NY,
321 USA) prior to LC-MSMS analysis.

322 Water-soluble B vitamins (B3, B6 and B9) analyses in CM and EYCF groups were
323 performed on an Acquity I-class UPLC system (Waters, Milford, MA, USA) composed of a
324 binary solvent pump, a sample manager with a fixed-loop injection system (SM-FL) set at
325 6°C, and a column oven equipped with an active preheater set at 40°C. Separations were
326 performed on an ACE Excel, 1.7 μm , C18-AR 100 x 3.0 mm column (ACE, UK) in gradient
327 mode using solutions containing 1% Acetic acid, 0.4% Formic acid and 0.2%
328 Heptafluorobutyric acid (HFBA) in Milli-Q water (Merck®, DE), and Methanol as mobile
329 phases. A constant flow rate of 450 $\mu\text{L}/\text{min}$ was used and a volume of 2 μL was
330 systematically injected. The UPLC system was hyphenated to a Xevo TQ-XS triple
331 quadrupole mass spectrometer (Waters, Milford, MA, USA) equipped with an Electrospray
332 Ionization (ESI) source. Argon was used as collision gas and Multiple Reaction Monitoring
333 (MRM) transitions were experimentally determined for each compound. Data were acquired
334 using MassLynx software (Waters, Wilmslow, UK), and chromatographic peaks were

335 integrated with TargetLynx (Waters, Wilmslow, UK). A calibration curve is built using
336 response (ratio of analyte area and internal standard area) and theoretical concentration of
337 each calibration point, then weighted. QCs and samples are quantified using the calibration
338 curve and reported in ng/ml.

339 For vitamin D (25-hydroxycholecalciferol) levels, blood samples were centrifuged and sent
340 on ice to Asian Hospital and Medical Center in Muntinlupa City. Concentrations of serum
341 25(OH)D were measured using the DiaSorin radioimmunoassay (RIA) method. The intra-
342 assay coefficient of variation (CV) was less than 2%. All laboratory technicians were blinded
343 to the case status. Deficiency was defined as levels below 20ng/mL and insufficiency as
344 levels between 20 to 30 ng/mL.

345

346 Measurement of Fatty acid and mineral excretion in feces

347 A 27g stool sample was collected by the parents at home and stored in the freezer until
348 picked up by study staff. The samples were stored locally in a -80 °C freezer at the study site
349 in the Philippines, and shipped on dry ice to Eurofins (Madison, WI, USA) for analysis of
350 total fatty acid soaps, and mineral content (total calcium, magnesium and phosphorus), in CM
351 and EYCF groups. The dried stool sample was extracted and neutral lipids including non-
352 soap free fatty acids were obtained by solvent reflux. The remaining sample was treated by
353 acetic acid to release the fatty acid soaps, which were obtained by a second solvent reflux
354 step, as described previously (43). Total fatty acid soaps were calculated based on the sum of
355 all measured individual fatty acid soaps and was normalized to gram of dry stool weight in
356 the acid form and expressed as mg/g. The limit of quantification for major fatty acids is a
357 standard 0.05 mg/g based on a 0.5 gram sample weight. Mineral analyses were performed by
358 ICP.

359

360 Statistical analysis on primary and secondary outcomes

361 The primary outcome was tibia SOS measurements after 6 months of product intake. The
362 estimated effect for the primary endpoint was obtained using a mixed model for repeated
363 measurements (MMRM) for the tibia SOS measurements at 3 months and 6 months. The
364 fixed covariates of the MMRM were: randomized treatment (EYCF or CM), visit (3 months
365 or 6 months), visit in interaction with treatment, baseline tibia SOS measurement (at
366 enrollment), and sex. Participant identification number was used as a random effect to
367 account for the intra-participant correlation. No imputation methods were used, assuming that
368 the data was missing at random, and that the resulting estimator of the mixed linear model is
369 unbiased under this assumption. Significance of the estimated effect for the primary endpoint
370 was tested at 5% level and no multiplicity adjustment was needed.

371 All conclusions for the primary outcome were based on the intention-to-treat analysis
372 population (ITT), which quantified the average treatment effect in all randomized participants
373 regardless of adherence to treatment. A supportive analysis for the primary outcome was
374 carried out on the per-protocol set (PP), consisting of all children with at least 70%
375 compliance for the product intake, no consumption of other fortified milk and no intake of
376 vitamin supplements. No difference on the primary outcome between ITT and PP analysis
377 was observed.

378 Continuous secondary endpoints were analyzed using MMRM, when repeated measurements
379 were performed at both 3 months and 6 months visits, with same covariates as for the primary
380 endpoint. For continuous secondary outcomes measured only at baseline and at end of the
381 study (6-months visit), an analysis of covariance model was used to estimate the treatment
382 effect. The factors of the analysis of covariance model were randomized treatment, sex and
383 baseline endpoint. When necessary, a natural logarithm transformation was performed to
384 meet the assumptions of homoskedasticity of residuals. Estimated effects of secondary

385 outcomes were tested at 5% without adjustment for multiplicity. No imputation for missing
386 data was performed on secondary endpoints.

387 Association between different clinical outcomes were performed using both Pearson and
388 Spearman correlation coefficient, significance of the correlation was tested at 5% level
389 without adjustment for multiplicity.

390 Subjects in the formula group are randomized to receive the experimental young child
391 formula or the minimally fortified milk. Subjects belonging to the reference group (REF) are
392 not randomized, they are recruited in the trial and they continue their habitual diet, which
393 may or may not consist of cow's milk-based products.

394 In this situation, confounding can occur if some covariates are related to both the treatment
395 assignment (exposed to either EYCF or CM) and the outcome. In the presence of
396 confounding, propensity score methods are used to remove the effects of confounding when
397 estimating the effect of treatment. For this analysis gender, gestational age (GA), delivery
398 mode, breastfeeding history, age at enrollment (months), BMI at baseline were used as
399 variables to build the propensity scores.

400 First a comparative model without adjustment was carried out. After which, a model
401 including the computed propensity scores as a covariate was carried out. Then a model
402 including the computed propensity score as a weight (inverse probability of treatment
403 weighing method) was carried out. The three models included as covariates by default the
404 gender, gestational age (GA), weight at birth, delivery mode, breastfeeding history, age at
405 enrollment (months), BMI at baseline. The comparison between the first and the two next
406 models highlight a part of the bias introduced by the lack of randomization. The results were
407 reported when the three models lead to similar conclusions, for a robust interpretation of the
408 results.

409

410 Microbiome analysis

411 Out of 278 screened subjects, a total of 220 participants (81%) provided stool samples at all
412 timepoints, while 41 participants (6%) provided samples only at baseline. Stool samples were
413 subjected to DNA extraction, library preparation and shotgun metagenomics sequencing
414 similarly to Capeding *et al.* (44) with the exception that DNA extraction was performed using
415 the NucleoSpin 96 Stool (Macherey-Nagel) kit. After removing low-quality reads and reads
416 mapping to the human genome (GRCh38), the remaining reads were aligned to the Clinical
417 Microbiomics in-house extended infant fecal microbiome gene catalog (20,992,486 microbial
418 genes) allowing for taxonomical profiling of corresponding set of 1472 metagenomics
419 species (MGS) (45). All MGS relative abundances are shared in Supplementary Table S2.

420

421 Metabolome analysis

422 Stool metabolomics were performed untargeted for semi-polar metabolites following an
423 analytical protocol adapted to a UHPLC system (Vanquish, Thermo Fisher Scientific)
424 coupled with a high-resolution quadrupole-orbitrap mass spectrometer (Orbitrap Exploris 240
425 MS, Thermo Fisher Scientific). Data was processed with Compound Discoverer (3.2, Thermo
426 Fisher Scientific) and MS-Omics software, with compound annotations based on the MS-
427 Omics internal spectral library, mzCloud, the Human metabolome database (HMDB, version
428 5.0) and the FoodDB.

429 Short chain fatty acid analysis of Acetic acid, Formic acid, Propanoic acid, 2-
430 Methylpropanoic acid, Butanoic acid, 3-Methylbutanoic acid, Pentanoic acid, 4-
431 Methylpentanoic acid, Hexanoic acid, Heptanoic acid, and p-Cresol was performed in a
432 targeted manner on a high-polarity column (Zebron™ ZB-FFAP, GC Cap. Column 30 m x
433 0.25 mm x 0.25 µm) installed in a GC (7890B, Agilent) coupled with a time of flight MS
434 (Pegasus® BT, LECO). Raw GC-MS data were processed and quantified in Skyline 22.2

435 (Adams et al. 2020, PMID: 31984744) and the PARADISE software (v2.6) developed by MS-
436 Omics and collaborators. Finally, clusters of co-abundant compounds were identified using
437 the weighted correlation network analysis (WGCNA) framework as implemented in the
438 WGCNA R package (Langfelder & Horvath, 2008), applied on the merged data set including
439 the SCFA processed peak areas and the semi-polar processed PQN peak areas. A signed,
440 weighted compound co-abundance correlation network using biweight midcorrelation, with
441 <5% of the individuals regarded as outliers was calculated across all included samples using
442 all pairwise observations. A scale-free topology criterion (R^2 -cutoff for scale-free
443 topology ≥ 0.8) was used to choose the soft threshold, resulting in $\beta = 41$. Clusters of
444 positively correlated compounds were identified with the dynamic hybrid tree-cutting
445 algorithm (46), using a deepSplit of 2, a minimum cluster size of 10 and the partitioning
446 around medoids option turned on. The profile of each metabolite module was summarized by
447 the module eigenvector, i.e. the first principal component of the metabolite abundances
448 across samples. Pairs of modules were subsequently merged if the correlation between the
449 modules' eigenvectors exceeded 0.85. The resulting metabolite modules were named 'MXX',
450 where 'XX' is an integer. Compounds that did not fit the clustering criteria were assigned to a
451 leftover group named 'M0'. Complete metabolite data is available upon request.

452

453 **Integration of microbiome, metabolome & clinical outcomes**

454 Microbial abundances for taxa present in at least 10% of samples were centered log-ratio
455 (CLR) transformed after replacing all zeroes with half the lowest observed non-zero
456 abundance per taxon (47). Semi-polar metabolite intensities were power transformed (Box-
457 Cox). SCFA quantifications were log2 transformed. To be robust against outliers in the data,
458 winsorization was performed, capping the transformed abundances at their 3rd and 97th
459 percentile.

460 The intervention effect on the microbial abundances and the metabolite intensities was
461 estimated with cross-sectional linear models with the covariates: intervention group (CM or
462 EYCF) and sex.

463 Correlations between microbial abundances, metabolite intensities and clinical outcomes
464 were estimated on samples at all time points and the two intervention groups collectively
465 using linear mixed models adjusting for sex as a fixed effect and participant as a random
466 effect, with effect sizes reported as partial Pearson correlation coefficients (obtaining by
467 scaling the T-values of the linear model).

468 All models including metabolite intensities have the additional fixed effect covariate: storage
469 time of metabolome sample. All models including microbial abundances used a
470 compositional bias correction based on LinDA (48).

471 P-values were adjusted for multiple testing by the FDR method (49). These adjusted P-values
472 are referred to as Q-values. Adjustments were performed separately for each visit, each
473 microbial taxonomy level, and for the set of WGCNA modules, as well as for each annotation
474 level of the metabolites (SCFA, 1, 2a, 2b, 3), where relevant.

475 The alpha diversity of the microbial composition was estimated with richness and Shannon
476 index, both estimated at gene-level and species-level, and with species-level Faith's PD.
477 Weighted UniFrac distances were used for beta diversity analysis.

478 Procrustes analysis was performed on the first two principal co-ordinates of the weighted
479 UniFrac distance matrix (microbial composition) and the first two dimensions of a
480 redundancy analysis (for metabolite intensities) using protest from the vegan package with
481 999 permutations.

482

483 Association of *L. reuteri* increase vs. non-increase groups with clinical
484 outcomes

485 Statistical comparisons between samples displaying an increase in *L. reuteri*, or a lack
486 thereof, between baseline and after 6 months of intervention, were run using the same
487 approach as in the section “Statistical analysis on primary and secondary outcomes”.

488

489

490 Results

491 We have previously shown *in vitro* that administration of a synbiotic consisting of *L.*
492 *reuteri* and GOS improves osteoblastogenesis (20). Prior to assessing the clinical efficacy of
493 this synbiotic on muscle strength in toddlers, we evaluated its impact on muscle progenitor
494 cells, key drivers of muscle development.

495

496 Experimental formula positively impacts myogenesis *in vitro*

497 Human myoblasts exposed to the product of *in vitro* fermentation of the experimental
498 formula, containing GOS + *L. reuteri*, showed a statistically significant increase in the fusion
499 index of myotubes (+10% as compared to milk matrix alone versus non-statistical significant
500 increase by GOS and *L. reuteri* separately, by 4.5% and 2.4%, respectively, Fig.S1A, C) and
501 the myotube total area (+18% as compared to milk matrix alone versus non-significant
502 increase by GOS and *L. reuteri* alone by 5.8% and 3.8%, respectively, Fig.S1B, C).

503

504 Clinical trial population

505 A total of 273 of 278 screened toddlers were eligible for the study (Fig. 1A). Of the 273
506 toddlers, 182 were randomized to experimental young child formula (EYCF) or a minimally
507 fortified control milk (CM), whereas 91 remained under their habitual diet (REF). Study

508 participants were included between June 2021 and March 2022 and completed their 6-month
509 visit between November 2021 and August 2022. The FAS analysis included all study subjects
510 (n = 138) who were randomized to the EYCF or CM. The study groups were well balanced
511 with regard to baseline characteristics (Supplementary table S3). All study participants were
512 Asian. A total of 107 (59%) subjects completed the 6 months intervention period in the study,
513 of whom 51 had been randomized to EYCF and 56 to CM. Four participants dropped out in
514 the REF group. Four participants had a major protocol deviation defined as a compliance rate
515 of <70%.

516

517 **Experimental young child formula increases bone and muscle strength**

518 The mean relative change in tibia SOS at 6 months of intervention in EYCF was 58.91m/s
519 (95% confidence interval [CI]: 21.34, 96.48; p=0.002 compared to CM) (Fig. 1C).

520 After 3 months of intervention, the difference was already significant reaching 53.00 m/s
521 (95% CI: 7.05, 98.95; p=0.024 in EYCF compared to CM) (Fig. 1D). Tibia SOS was
522 significantly greater in EYCF compared to REF after 6 months of intervention (p=0.007;
523 Supplementary table S4, S5) while no difference was observed between the CM and REF.
524 Bone turnover index was also significantly higher in EYCF compared to CM (+25%, p=0.02)
525 (Fig. 1E) after 6 months of intervention, while no difference was observed between CM and
526 REF (Supplementary table S4, S5).

527 Secondary outcomes, including bone growth (head circumference, tibia & radius
528 length, Fig. 1F-G, Supplementary table S4, S5) and body growth (height & weight for age Z
529 score, figure 1H-I) were not significantly different between EYCF and CM. However, both
530 CM and EYCF groups showed higher bone and body growth than REF after 6 months of
531 intervention (supplementary table S4, S5). Finally, muscle force of the right arm was higher
532 in EYCF than CM group by 11% (95% CI: [2%, 20%]; p=0.015) (Fig. 1J), after 6 months of

533 intervention, while no difference was observed between CM and REF (Supplementary table
534 S4, S5).

535

536 Vitamins and minerals levels in experimental young child formula do not 537 drive effect on bone and muscle strength

538 To determine whether the observed improvement of bone and muscle strength in EYCF was
539 associated to higher vitamin levels, and/or lower intakes of sn-1,3 palmitate, we measured
540 vitamins D, B3, B6 concentrations and excretion of fecal calcium fatty acid soaps. After 6
541 months of intervention, Vitamin D levels were 31.3, 36.5, and 32.7 ng/mL in the CM, EYCF,
542 and REF groups, respectively. Vitamin D levels were 17% (95% CI: [11%, 23%]) higher in
543 the EYCF compared to CM ($p < 0.0001$) (Fig. 2A) and 10% (95% CI: [10%, 15%]) higher
544 compared to REF ($p < 0.001$) (Supplementary table S6).

545 This effect totally abolished deficiency and reduced insufficiency of vitamin D by 52%
546 reported at baseline (Supplementary Fig. S1D) in the EYCF. However, blood vitamin D
547 levels were not associated to tibia SOS and muscle force (Fig. 2B-2C).

548 A specific ratio of vitamins B3/B6, previously described to stimulate muscle regeneration
549 (50), was increased in EYCF after 6 months of intervention (Fig. 2D). However, no
550 association was found with tibia SOS, handgrip, radius SOS and radius length, and only a
551 mild correlation was found with the tibia length (Supplementary table S7). Finally, folic acid
552 level was not different between CM and EYCF (Fig. 2E).

553 Total fecal fatty acids soaps levels did not differ at baseline between groups, whereas they
554 significantly lowered after 6 months of intervention in EYCF compared to CM ($p < 0.001$, Fig.
555 2F). However, calcium excretion was not significantly different between groups after
556 adjustment by intake of the product (Fig. 2G). Magnesium and phosphorus excretion
557 appeared lower in EYCF compared to CM (Fig. 2H, 2I, $p < 0.01$). However, none of the
558 calcium and magnesium minerals nor total fatty acids soaps were associated with tibia/radius

559 SOS, muscle force or tibia/radius length and only phosphorus was mildly associated with
560 handgrip (Supplementary table S7).

561

562 The experimental young child formula induces a bifidogenic effect

563 Given the important link between microbiome and musculoskeletal development in
564 early life, we investigated whether the gut microbiome and metabolome of toddlers were
565 impacted by the nutritional intervention.

566 The gut microbiome composition of all children was overall not significantly different
567 between groups at baseline, as determined by alpha and beta diversity (Supplementary Fig.
568 S2, Supplementary table S8). After 6 months of intervention, toddlers consuming EYCF
569 showed a distinct microbial community compared to baseline ($P=0.0199$, Supplementary Fig.
570 S2, Supplementary table S8). Looking at the 16 species significantly higher in EYCF
571 compared to CM after 6 months of intervention (Fig. 3A), a notably significant increase was
572 observed in *L. reuteri* ($Q=6.10e-14$, effect size=4.23), and in several bifidobacteria such as *B.*
573 *breve* ($Q=0.047$, effect size=3.57), *B. bifidum* ($Q=0.038$, effect size=3.40), *Bifidobacterium*
574 *longum* spp. ($Q=0.021$, effect size=2.56), *B. longum* subsp. *longum* ($Q=0.038$, effect
575 size=1.85), overall suggesting a bifidogenic effect of the intervention (Fig. 3A). Other taxa
576 significantly enriched in EYCF include 3 species belonging to the *Bacteroides* genus
577 ($Q=0.202$, effect size=1.04). In CM, 21 species were significantly higher than in EYCF,
578 including 8 species belonging to the *Streptococcus* genus ($Q=3.84e-05$, effect size=-2.17)
579 (Statistics for all taxonomic levels are reported in Supplementary table S9).

580

581 The experimental young child formula altered the microbial metabolism 582 of amino acids

583 Given the changes in microbiome composition, we further investigated the impact of
584 the intervention on its functionality by exploring the fecal metabolome (Fig. 3B).

585 Within it, 266 metabolites were found to significantly differ between EYCF and CM
586 at 6-month visit, of which 69 had an unambiguous annotation (Fig. 3B). Of note, metabolites
587 like pipercolinic acid ($Q=2.83e-06$, effect size=0.99), indole-3-carboxyaldehyde ($Q=0.013$,
588 effect size=0.52), IPA (indole-3-propionic acid, ($Q=0.007$, effect size=0.61), ILA (indole-3-
589 lactic acid, $Q=0.04$, effect size=0.39) and lysine ($Q=0.001$, effect size=0.64) were all
590 significantly increased in EYCF compared to CM. Other metabolites strongly associated with
591 the EYCF group included several amino acids ($Q<0.06$, effect size 0.41-0.71), and N-
592 acetylated amino acids ($Q<0.09$, effect size 0.35-0.79) (Fig. 3B, Statistics for all metabolites
593 are reported in Supplementary table S10).

594

595 The experimental young child formula promotes microbiome & 596 metabolites changes that are associated to clinical outcomes

597 We then assessed whether the metabolomic changes observed were associated with
598 changes in microbiota composition. In this analysis, we found a significant correlation
599 between microbiome and metabolome at all timepoints, suggesting that children with similar
600 microbiota compositions have similar metabolomic profiles (all $p<0.02$, correlation between
601 0.27 and 0.47 depending on sample subset, see Supplementary table S11). Looking at
602 correlations between species and metabolites significantly increased in EYCF at 6 months
603 (Fig. 3C), we observed a majority of these metabolites correlating with the most enriched
604 species, namely: 42 out of 45 significantly correlated with *Bifidobacterium breve*, 27 with *L.*
605 *reuteri* and 26 with *B. longum* subsp. *longum* – suggesting that the increase of *L. reuteri* and
606 bifidobacteria caused by the EYCF intervention is associated with a shift in metabolomic
607 profiles. Of note, abovementioned metabolites known to have an impact on bone and muscle
608 development (i.e. pipercolinic acid, lysine, indole-3-carboxyaldehyde, IPA, and ILA) all
609 significantly correlated positively with *B. breve*, *B. longum* subsp. *longum* and some to *L.*
610 *reuteri* and *B. bifidum* too, although with a low effect size ($Q<0.07$, effect size 0.18-0.41).

611 We further determined if the observed taxonomic and metabolic differences were
612 associated to clinical outcomes related to bone and muscle strength. 37 species were
613 significantly associated to at least one clinical outcome and one metabolite (Fig. 4A),
614 including several which were significantly increased after 6 months of intervention in EYCF
615 compared to CM. Notably, *L. reuteri* showed significant associations with 4 of the 5
616 measured clinical outcomes (tibia length, radius length, radius SOS and handgrip strength,
617 $Q < 0.07$). *Bifidobacterium longum* subsp. *longum* was significantly associated with tibia
618 length and radius length ($Q < 0.004$), and nominally also with handgrip ($P = 0.02$, $Q = 0.43$).
619 Worth noting, tibia length was the outcome associated with the highest number of species (32
620 out of 37, 12 of which were positively correlated to tibia length and significantly higher in
621 EYCF compared to CM after 6 months of intervention). All statistical associations between
622 microbiome species and clinical outcomes can be found in the Supplementary table S12.

623 We also assessed the relationship between clinical outcomes and fecal metabolites,
624 with 15 metabolites significantly associated with at least one clinical outcome (Fig. 4A). Of
625 interest, several metabolites that were significantly increased in the EYCF group at 6 months
626 compared to CM were associated with at least one clinical outcome. For example, indole-3-
627 carboxyldehyde was significantly associated with tibia length ($Q = 0.058$) and ILA with
628 handgrip strength ($Q = 0.012$) and nominally to radius length ($P = 0.046$, $Q = 0.012$). Of note, 8
629 metabolites such as indole-3-carboxyaldehyde, tyrosine, citrulline, 3-hydroxypyridine or 4-
630 hydroxybenzaldehyde positively correlated with tibia SOS, although only nominally
631 significant ($P < 0.05$, $Q \leq 1$). All statistical associations between fecal metabolites and clinical
632 outcomes can be found in the Supplemental Table S13.

633

634 *L. reuteri* abundance increases are associated with clinical outcomes

635 While there was an association between EYCF and tibia SOS as well as handgrip
636 strength, this relationship was not observed in all the children in the EYCF group. To better
637 understand this effect, we investigated whether it was driven by an increased abundance of *L.*
638 *reuteri* throughout the intervention period. For this, we classified the overall study population
639 into two categories: “increase” when *L. reuteri* abundance (derived from the associated
640 rarefied species abundance) was increased between baseline and 6 months, and “non-
641 increase” when *L. reuteri* did not increase. Notably, *L. reuteri* abundance increased between
642 baseline and 6 months in half of the children in the EYCF group. Participants in which *L.*
643 *reuteri* increased in abundance over time showed a significant increase of handgrip force
644 (mean increase=0.3kg, Fig. 4B), tibia SOS (mean increase = 55 m/s, Fig. 4C) and vitamin D
645 (mean increase = 3ng/mL, Fig. 4D), with most subjects indeed belonging to the EYCF group.
646 However, in this stratified analysis we did not see associations with bone length or bone
647 radius, despite their association with overall *L. reuteri* abundance. All of these trends persist
648 when including samples from the reference group, except for handgrip force which was no
649 longer significant ($P < 0.1$, Supplementary table S14).

650

651 Consumption of EYCF is safe and well tolerated

652 Mean total TGCQ scores were low at baseline and remained low after 3 and 6 months of
653 intervention, indicating maintenance of good GI tolerance in these healthy children. No
654 significant difference in total TGCQ scores was observed between the EYCF and CM groups.
655 After 3 months of intervention, mean (\pm SD) scores were 10.64 ± 2.28 in EYCF vs. $10.85 \pm$
656 1.96 in CM; $P=0.236$, and after 6 months scores were 10.62 ± 1.63 in EYCF vs. 10.57 ± 1.44
657 in CM; $P=1$, Supplementary table S15, S16). The mean number of stools per day was
658 approximately 1.3 after 3 and 6 months of intervention and not significantly different

659 between treatment groups. Mean stool consistency scores ranged from 3.5 – 3.87 or between
660 “mushy-soft” and “formed” at Visits 2 and 3 in both intervention groups. After 3 months of
661 intervention, stool consistency scores were significantly lower, indicating softer stools, in
662 EYCF vs CM (3.5 ± 0.62 vs 3.78 ± 0.39 , $P < 0.001$, Supplementary table S15, S16). There was
663 no significant difference in mean stool consistency score after 6 months of intervention (3.72
664 ± 0.40 vs 3.87 ± 0.37 , $P = 0.079$, Supplementary table S15, S16).

665 The overall incidence of AEs was comparable between the groups. In the EYCF group, a
666 total of 42 events occurred in 35 participants, while a total of 35 events occurred in 31
667 participants in the CM group. No AE was considered to be related to the study products and
668 no serious adverse event was reported in this trial.

669

670 Discussion

671 Toddlerhood is a critical window for bone and muscle development, coinciding with
672 the establishment of a more adult-type microbiome (51). Previous reports highlight the
673 existence of a gut-musculoskeletal axis in elderly people (11), while our study is -to the best
674 of our knowledge- the first one exploring this axis in early life in a controlled randomized
675 trial.

676 In this study, an experimental young child formula (EYCF) containing a synbiotic
677 composed of GOS and *L. reuteri* was shown to improve bone quality and muscle strength
678 after 6 months of intake. We found that this formula improved tibia SOS compared to a
679 minimally fortified control milk (CM) after 6 months of intervention and, more importantly,
680 exhibited a gain in tibia SOS by 4 times compared to the habitual diet group. Handgrip
681 strength after 6 months was increased 1.7 times compared to control and 1.4 times compared
682 to habitual diet. The results of this clinical study have shown that this experimental young

683 child formula containing a synbiotic of GOS and *L. reuteri* is efficient in improving bone and
684 muscle strength acquisition, within normal physiological growth rates represented by the
685 habitual diet reference group. Furthermore, the latter are consistent with previous studies in
686 toddlers reporting increases of tibia SOS at a rate of 2.1% per year (39) and handgrip force at
687 a rate of 30% per year (52).

688 Interestingly, EYCF containing 520IU/l Vitamin D significantly increased circulating
689 levels of vitamin D by 17%, effectively reduced insufficiency by 52% and abolished
690 deficiency. Meanwhile, in a previous study supplementation of 400IU and 1000IU,
691 respectively increased vitamin D levels by 8.2% and 18% in 12-30 months old toddlers (53).
692 The similar increase in our study to the latter higher dose suggests a potential improvement of
693 Vitamin D absorption when co-administered with a synbiotic, which is further supported by
694 another previous RCT combining a probiotic and vitamin D intervention (54). However, in
695 our study, vitamin D levels or even B vitamin blood levels did not associate to muscle
696 strength or bone length and quality.

697 Fecal soap fatty acids have been shown to decrease mineral absorption in infants via
698 formation of fatty acid mineral soaps (55). In our study, excretion of fatty acid mineral soaps
699 was significantly decreased in EYCF compared to CM, but did not impact fecal calcium
700 levels and was not associated with bone quality or muscle strength.

701

702 We also demonstrated that the supplementation with a young child formula with *L.*
703 *reuteri* and GOS had a significant impact on microbiome composition both compositionally
704 and functionally. Indeed, supplementation of EYCF with *L. reuteri* and GOS resulted in a
705 bifidogenic effect previously reported with GOS alone (56) and *L. reuteri* alone (57), with
706 not only *L. reuteri* being significantly increased in EYCF subjects but also several other

707 members of the *Bifidobacterium* genus, some being reported in clinical studies to positively
708 impact bone mass (58) and muscle function (59) in adults.

709 The analysis of the fecal metabolome showed that the supplementation with a young child
710 formula with *L. reuteri* and GOS also promoted significant increases in metabolites such as
711 pipercolinic acid, lysine, indole-3-carboxyaldehyde, known to be positively associated to bone
712 (10) and muscle outcomes (60). These metabolites are part of the tryptophane metabolism
713 pathway, i.e. either direct (indoles) and indirect (pipercolinic acid, lysine) derivatives.
714 Interestingly, an increasing number of studies indicate that amino acid metabolism is crucial
715 for bone and muscle development and homeostasis, particularly through autophagy mediated
716 effects (61). Tryptophan metabolism through the kynurenine pathway is one major known
717 factor in promoting bone-aging phenotypes but also to stimulate bone anabolism during
718 growth through activation of the NAD signaling pathway (62, 63). The multiple faces of
719 tryptophan in muscle biology also indicate the ability of tryptophan metabolites to improve
720 muscle growth, protein synthesis as well as antioxidant capacity, which might be partly
721 related to myogenic regulatory factors, IGF/PIK3Ca/AKT/TOR and Keap1/Nrf2 signaling
722 pathways (64).

723 The correlation between some specific features of the microbiome and the
724 metabolome affected by our intervention further supports the importance of using a holistic
725 approach, including microbiome ecology and functionality to more comprehensively assess
726 the impact of a nutritional intervention. This analysis allowed us to show that several of the
727 taxa and metabolites that were significantly impacted by the nutritional intervention are
728 strongly linked to muscle and bone metabolism. Some examples stand out, like ILA and
729 indole-3-carboxyaldehyde, as well as precursors and metabolites related to amino acid
730 metabolism, such as citrulline, which has been clinically shown to improve muscle
731 performance, recovery and protein synthesis (65, 66), as well as fracture healing and

732 mineralization in preclinical models (67, 68). In our study, we too could observe some
733 associations to health outcomes; for example citrulline was associated with tibia SOS, and 4-
734 hydroxyproline, a metabolite found in collagen, was positively associated with handgrip,
735 consistent with a previous intervention with collagen peptide in sarcopenic men (69). Also,
736 we report for the first time, to our knowledge, two metabolite associations,
737 4-Hydroxybenzaldehyde with bone quality and 4-Hydroxybenzoic acid with muscle
738 strength, both being present as aromatic compounds in plants.

739 It is interesting to note that, in our study, different metabolites associate to muscle and
740 tibia quality. However, radius quality (a non-weight bearing bone) and muscle strength
741 shared associations with the same metabolites, namely positively and negatively with
742 DL-4-hydroxyphenyllactic acid and phenethylamine, respectively. This highlights the
743 importance of diverse microbes and metabolites to impact the gut-musculoskeletal axis.

744 In addition, we could also show a link between *L. reuteri* increase from baseline to 6-
745 months and key clinical outcomes like handgrip strength, tibia SOS and vitamin D, especially
746 in EYCF. Further analysis using qPCR is needed to confirm the origin of the *L. reuteri* strain,
747 i.e. from the synbiotic intervention or from other sources, as some samples in the control
748 group (3 out of 69 participants) also showed an increase in *L. reuteri* abundance.

749 Here we provide further *in vitro* evidence for a synergistic effect of *L. reuteri* and GOS on
750 muscle stem cell fusion and osteocalcin secretion from osteoblast, two key cell processes for
751 muscle and bone development. Even if we showed an effect of EYCF supplemented with the
752 *L. reuteri* and GOS synbiotic on clinical outcomes and the microbiome, the synergistic
753 effects was not assessed.

754

755 In conclusion, we have shown clinically that a young child formula supplemented
756 with a synbiotic consisting of *L. reuteri* and GOS is safe and well tolerated, can mitigate

757 vitamin D insufficiency and supports healthy and strong muscle and bone development. We
758 further substantiated the presence of a gut-musculoskeletal axis in toddlers, as the nutritional
759 intervention significantly affected the microbiome and the metabolome of the toddlers in the
760 ECYF group in a correlated manner. Furthermore, several metabolites and taxa further
761 correlated to muscle and bone outcomes. Our study additionally provides novel mechanistic
762 insights as to how microbiome-modulating interventions can benefit bone and muscle
763 development in early life.

764 Figure legends

765 **Figure 1. Subjects and design of the clinical trial and effect of the experimental blend on**
766 **bone and muscle clinical outcomes.** (A) A total of 273 toddlers were enrolled into the study;
767 182 toddlers were randomized to one of the feeding groups and 91 toddlers were enrolled in
768 parallel as a reference population. Randomized toddlers were assigned to either a minimally
769 fortified cow milk (CM, n=91) or experimental young child formula group (EYCF, n=91).
770 Overall, 225 (82%) subjects completed the study. In the FAS, the retention rate was 77% in
771 both CM & EYCF groups. Across all groups, 48 toddlers (22 each in CM and EYCF, 4 in
772 REF) withdrew from the study with the common reasons of issues with taste (n=16; 33%)
773 and transfer to province/other country (n=15; 31%). Other reasons for withdrawal included
774 relatives' disapproval (n=9; 19%), unable to comply (n=4; 8%), adverse events (n=2; 4%),
775 and preference to solid food (n=2; 4%). (B) Schematic of experimental design. (C) Tibia
776 speed of sound (SOS) measured by quantitative ultrasound after 6 months of intervention. (D)
777 Longitudinal tibia SOS. (E) Bone turnover marker (CTx-P1NP)/P1NP. CTx: carboxy-
778 terminal collagen crosslinks, P1NP: Procollagen type I N-terminal propeptide. C(D-H)
779 Anthropometric outcomes: (F) Head circumference, (G) Tibia length, (H) Height for age, (I)
780 Weight for age. (J) Muscle force (right arm) measured by handgrip. For all outcome, EYCF
781 and CM groups n=69. Data are presented as mean \pm SD, * P<0.05, ** P<0.01 compared to
782 CM group.

783 **Figure 2. Influence of «non synbiotic elements» in the blend on bone & muscle readouts.**
784 (A) 25 hydroxy vitamin D3 levels in blood at baseline and after 6 months of intervention. (B)
785 Lack of association between 25 hydroxy vitamin D3 and tibia SOS after 6 months of
786 intervention. (C) Lack of association between 25 hydroxy vitamin D3 and handgrip force
787 after 6 months of intervention. Blood vitamins measure showing the specific ratio of vitamin
788 B3 and B6 (D), Folic acid (E) at baseline and after 6 months of intervention. (F) Soap Fatty
789 Acids levels in Infant Stool at baseline and after 6 months of intervention. (G-I) Respectively
790 calcium, magnesium and phosphorus excretion levels in feces adjust by product intake. For
791 all outcome, EYCF n=68 and CM n=69. Data are presented as mean \pm SD, * P<0.05, **
792 P<0.01, *** P<0.001 and **** P<0.0001 compared to CM group.

793 **Figure 3. EYCF consumption impacts both the fecal microbiome and metabolome.**
794 Volcano plots of (A) the fecal microbiome and (B) the fecal metabolome depicting the
795 difference between control-fed and EYCF-fed infants at each visit (421 samples in total, 208
796 EYCF and 213 CM). Group comparison was performed using a linear model at each visit
797 with intervention group and sex as confounders, adding storage time as confounder for the
798 fecal metabolome, filtering species prevalence at 10% minimum (C) Associations between
799 the fecal metagenome and metabolome features significantly increased in the EYCF group at
800 V3 using a linear model with sex and storage time as confounders.

801

802 **Figure 4. Changes in fecal microbiome and metabolome are associated to the nutritional**
803 **intervention and clinical outcomes.** (A) Correlations between metagenome, metabolome
804 and clinical outcomes (see methods for more details on the statistical approach) (B-D)
805 Comparison of in handgrip force (B), tibia SOS (C), and Vitamin D (D) between samples
806 showing an increase in *L. reuteri* after 6 months compared to baseline (“Increase”, n=37) and

807 samples not showing an increase (“Non-increase”, n=101). Non-significant associations are
808 shown in Supplementary table 14.
809

810 Supplemental figures & tables

811 **Supplemental Figure S1. EYCF impacts muscle development in vitro.** (A) Fusion index
812 of myotube after 6 days of treatment with final product of ex vivo colonic incubation (1%
813 final concentration). (B) Troponin T positive area of myotube after 6 days of treatment with
814 final product of ex vivo colonic incubation (1% final concentration). (C) Representative
815 images, scale bar: 200 μ m. MM=Milk matrix, GOS=Galacto-oligosaccharide. Experiments
816 performed with 2 different donors (10-12 replicates per donor). Statistical analysis: One-way
817 ANOVA Dunnett's test. **p<0.01, ***p<0.001.D) Vitamin D insufficiency (%) and
818 deficiency (%) among study participants (at baseline n=91 per group, at 6 months n= 87
819 (REF), 69 (CM), 69 (EYCF)

820 **Supplemental Figure S2. Alpha and beta diversity of subjects grouped by intervention**
821 **at baseline.** (A) Alpha-diversity is represented by boxplots showing differences in species
822 (MGS) richness, species (MGS) diversity (Shannon and Faith's) as well as gene richness and
823 diversity (Shannon). Intervention groups were compared by Kruskal-Wallis and Dunn's test.
824 No significant differences were observed for any alpha-diversity metric at baseline between
825 intervention groups. (B) Beta diversity is represented in a Principal Coordinates Analysis
826 (PCoA) based on weighted UniFrac distance between samples (color-coded by intervention
827 group).

828 **Supplemental table S1. Complete formulation of the control milk (CM) and the**
829 **experimental blend (EYCF).**

830 **Supplemental table S2. Relative species abundance for each sample.**

831 **Supplemental table S3. Demographics and baseline characteristics of subjects.**

832 Characteristics of the subjects in the ITT population.

833 **Supplemental table S4. Descriptive statistics of subjects at all visits.** Characteristics of the
834 subjects in the Reference group (REF), Control milk group (CM) and Experimental young
835 child formula group (EYCF) at baseline (V1), 3 months, if recorded, (V2) and 6 months (V3).

836 **Supplemental table S5. Clinical outcomes comparisons between the experimental and**
837 **control blends versus the habitual diet arm.** Comparison between Experimental young
838 child formula group and Reference group (EYCF – REF) or Control milk group and
839 Reference group (CM – REF) at 3 months, if recorded, (V2) and 6 months (V3) with
840 ANCOVA models

841 **Supplemental table S6. Comparisons of the blood vitamin D level between Experimental**
842 **group and Habitual diet group.** Comparison between Experimental group (EYCF) and
843 Habitual diet group (REF) at 6 months (V3) with ANCOVA models. Three models are
844 proposed to evaluate the differences between the Experimental group and the Reference
845 group, by taking into account that the Reference group was not randomized in this trial. The
846 first model, Model 1 is a model computed without propensity scores but includes as
847 covariates: Arm (Experimental or Reference), Visit (Visit 2 or Visit 3), Arm in interaction
848 with Visit, baseline Vitamin D level, measurement, sex, gestational age, delivery method,
849 duration of breastfeeding, age at baseline (measured in months), BMI (kg/m²) at enrolment

850 and vitamin D (ng/mL) at enrolment. The other two models have additional corrections: the
851 propensity scores included either as covariate in Model 2 or as weights in Model 3.

852 **Supplemental table S7. Correlation of the vitamin B3/B6 ratio and mineral excretion**
853 **(adjusted to intake) and the clinical outcome.** Spearman correlation of ratio of vitamin
854 B3/B6, the calcium, magnesium and phosphorus excretion adjusted to intake and the clinical
855 outcomes tibia SOS, Radius SOS, Tibia length, Radius length and Handgrip at 6 months (V3)
856 after the beginning of the trial. n=222 for the ratio B3/B6 (participants of the 3 groups were
857 measured), n=137 for the calcium, magnesium and phosphorus (only participants from the
858 CM and EYCF were measured)

859 **Supplemental table S8. PERMANOVA analysis on microbiome beta diversity.** P-values
860 for tests comparing beta-diversity between intervention groups, overall and pairwise

861 **Supplemental table S9. Comparison of microbiome taxonomic composition between**
862 **EYCF and CM.** Results of the linear model at each visit and taxonomic level.

863 **Supplemental table S10. Comparison of metabolome intensities between EYCF and**
864 **CM.** Results of the linear model at each visit comparing metabolites intensity between EYCF
865 and CM.

866 **Supplemental table S11. Procrustes analysis of microbiome-metabolome associations.**
867 Results from a Procrustes analysis stratified by intervention group and visit. P-values are
868 derived from 10 000 permutations (thus the smallest possible P-value being 0.0001)

869 **Supplemental table S12. Associations between microbiome taxonomic composition and**
870 **clinical outcomes.** Results of the linear model at species (MGS) level considering EYCF and
871 CM samples.

872 **Supplemental table S13. Associations between metabolome intensities and clinical**
873 **outcomes.** Results of the linear model for metabolites considering EYCF and CM samples.

874 **Supplemental table S14. Associations between *L. reuteri* “Increased” and “Non-increased”**
875 **groups and clinical outcomes.** The comparisons were run considering EYCF+CM samples,
876 and EYCF+CM+REF samples.

877 **Supplemental table S15. Stool consistency and Descriptive statistics for the TCGQ**
878 **questionnaire.** Average consistency of stools averaged over 3 days and Descriptive statistics
879 of the questionnaire “Toddler Gut Comfort Questionnaire” in the ITT population.

880 **Supplemental table S16. Comparison of stool consistency and Gastrointestinal total**
881 **score.** Stool consistency at baseline is extracted from “24h Recall GI Symptom and Behavior
882 Recall”, from question 3: “If yes, thinking about the past 24 hours, mark the one picture that
883 looks the most like your child’s stool”. The stool consistency was transformed using a 5-point
884 stool scale: 1=watery, 2=runny, 3=mushy soft, 4=formed, and 5=hard. The effect of treatment
885 group on stool consistency at V2 and V3 is evaluated based on a linear mixed model with a
886 log transformation of the response and the following explanatory variables: stool consistency
887 at baseline, treatment group, mode of delivery, gender, visit and interaction between
888 treatment and visit as covariates. A subject specific random effect is be included in order to
889 consider the repeated measurements.

890 Effect of treatment group on the log-transformed scores of GI TOTAL at V2 and V3 is
891 evaluated based on a linear mixed model, including GI TOTAL at baseline with log
892 transformation, treatment group, mode of delivery, gender, visit and interaction between
893 treatment and visit as covariates. A subject specific random effect is be included in order to
894 consider the repeated measurements.

895

896 Author contributions

897 NB, YC and MNH designed the study. MRC, JL and LP were responsible for recruiting
898 participants. MRC, JL and LP were investigators in the study and were responsible for
899 collecting data. NB, TD and MNH, were responsible for analyses of bone, muscles
900 outcomes, circulating levels of vitamin and fecal fatty soap and minerals. LFK had access to
901 raw data and were responsible for statistical analyses. NB, LS, TD, HLPT, LFK and MNH
902 drafted the manuscript and designed figures. NB, LFK, TD, LS and MNH have directly
903 accessed and verified the underlying data reported in the manuscript. JMM, AG and PRG
904 generated, analyzed and integrated microbiome and metabolome data. MGG oversaw the
905 microbiome analysis. MGG, LS and HLPT interpreted microbiome, metabolome and clinical
906 integration results. All authors had full access to all the data in the study and had final
907 responsibility for the decision to submit for publication.

908 Acknowledgements

909 Authors would like to thank Nestlé Research colleagues: Olivier Ciclet and Adrien Frezal for
910 technical expertise on B vitamins analyses, Dustin Larue and Francesca Giuffrida for fatty
911 acid soap analysis and interpretation, Héloïse Denurra for metabolomics results
912 interpretation, Ute Haeberlein Schwan for experimental product development, Flavien
913 Bermont and Aurelie Hermant for technical support on bone biomarkers analyses, Michael
914 Baruchet for sample preparation, and Eugenia Migliavacca for her support on statistical
915 analysis. We would like to thank Eline van der Beek, Irma Silva-Zolezzi and Laurence Biehl
916 for critical review of the manuscript. We thank Helle Pedersen and Thorsten Gravert (Clinical
917 Microbiomics) for their expert insights on metabolomics and statistical models associated,
918 and Claire Boulangé for supporting metabolomics interpretation.

919 **Data sharing statement**

920 All clinical outcomes, microbiome and metabolome data necessary to interpret the results
921 are included in supplementary data files or are available upon request in a deidentified and
922 anonymized format. No expiration date of data request is currently set once data are made
923 available.

924

925 **Funding**

926 Société des Produits Nestlé SA, Nestlé Research, Lausanne, CH.

927

928 **Conflict of interest**

929 Some authors are employees from Société des Produits Nestlé SA. Clinical Microbiomics
930 employees contributed within a service agreement contract.

931 References

932

- 933 1. Ma NS, Gordon CM. Pediatric osteoporosis: where are we now? . *J Pediatr*
934 *Endocrinol Metab.* 2012;161:983-90.
- 935 2. Shea JE, Miller SC. Skeletal function and structure: implications for tissue-targeted
936 therapeutics. *Adv Drug Deliv Rev* 2005;57(7):945-57.
- 937 3. Dibba B, Prentice A, Ceesay M, Stirling DM, Cole TJ, Poskitt EM. EFFECT OF
938 CALCIUM SUPPLEMENTATION ON BONE MINERAL ACCRETION IN GAMBIAN
939 CHILDREN ACCUSTOMED TO A LOW-CALCIUM DIE. *Am J Clin Nutr* 2000;71(2):544-9.
- 940 4. Uusi-Rasi K, Kärkkäinen MU, Lamberg-Allardt CJ. Calcium intake in health
941 maintenance - a systematic review. *Food Nutr Res* 2013;57:doi: 10.3402.
- 942 5. Lloyd T, Andon MB, Rollings N, Martel JK, Landis JR, Demers LM, et al. Calcium
943 supplementation and bone mineral density in adolescent girls. *JAMA.* 1993;270:841-4.
- 944 6. Mitchell DM, Jüppner H. Regulation of calcium homeostasis and bone metabolism in
945 the fetus and neonate. *Curr Opin Endocrinol Diabetes Obes.* 2010;17:25-30.
- 946 7. Lee WT, Leung SS, Leung DM, Wang SH, Xu YC, Zeng WP, Cheng JC. Bone
947 mineral acquisition in low calcium intake children following the withdrawal of calcium
948 supplement. *Acta Paediatr* 1997;86:570-6.
- 949 8. Rizzoli R, Bianchi ML, Garabédian M, McKay HA, Moreno LA. Maximizing bone
950 mineral mass gain during growth for the prevention of fractures in the adolescents and the
951 elderly. *Bone.* 2010;46(2):294-305.
- 952 9. He J, Xu S, Zhang B, Xiao C, Chen Z, Si F, et al. Gut microbiota and metabolite
953 alterations associated with reduced bone mineral density or bone metabolic indexes in
954 postmenopausal osteoporosis. *Aging (Albany NY).* 2020;12(9):8583-604.
- 955 10. Lu L, Chen X, Liu Y, Yu X. Gut microbiota and bone metabolism. *FASEB J.*
956 2021;35(7):e21740.
- 957 11. Wang Y, Li Y, Bo L, Zhou E, Chen Y, Naranmandakh S, et al. Progress of linking gut
958 microbiota and musculoskeletal health: casualty, mechanisms, and translational values. *Gut*
959 *Microbes* 2023;15(2):2263207.
- 960 12. Chonan O, Matsumoto K, Watanuki M. Effect of galactooligosaccharides on calcium
961 absorption and preventing bone loss in ovariectomized rats. . *Biosci Biotechnol Biochem*
962 1995;59:236–9.
- 963 13. Adam CL, Williams PA, Garden KE, Thomson LM, Ross AW. Dose-dependent
964 effects of a soluble dietary fibre (pectin) on food intake, adiposity, gut hypertrophy and gut
965 satiety hormone secretion in rats. *PLoS One* 2015;10(1):e0115438.
- 966 14. Singh A, Zapata RC, Pezeshki A, Reidelberger RD, Chelikani PK. Inulin fiber dose-
967 dependently modulates energy balance, glucose tolerance, gut microbiota, hormones and
968 diet preference in high-fat-fed male rats. *J Nutr Biochem* 2018;59:142-52.
- 969 15. Weaver CM, Martin BR, Nakatsu CH, Armstrong AP, Clavijo A, McCabe LD, et al.
970 Galactooligosaccharides improve mineral absorption and bone properties in growing rats
971 through gut fermentation. *Journal of agricultural and food chemistry.* 2011;59(12):6501-10.
- 972 16. Lobo AR, Filho JM, Alvares EP, Cocato ML, Colli C. Effects of dietary lipid
973 composition and inulin-type fructans on mineral bioavailability in growing rats. *Nutrition.*
974 2009;25:216–25.
- 975 17. Takahara S, Morohashi T, Sano T, Ohta A, Yamada S, Sasa R.
976 Fructooligosaccharide consumption enhances femoral bone volume and mineral
977 concentrations in rats. *J Nutr* 2000;130:1792–5.
- 978 18. Ribeiro JL, Santos TA, Garcia MT, Carvalho BFDC, Esteves JECS, Moraes RM,
979 Anbinder AL. Heat-killed *Limosilactobacillus reuteri* ATCC PTA 6475 prevents bone loss in
980 ovariectomized mice: A preliminary study. *PLoS One* 2024 19(5):e0304358.
- 981 19. Britton RA, Irwin R, Quach D, Schaefer L, Zhang J, Lee T, et al. Probiotic *L. reuteri*
982 Treatment Prevents Bone Loss in a Menopausal Ovariectomized Mouse Model. *Journal of*
983 *Cellular Physiology.* 2014;229(11):1822-30.











- 984 20. De Bruyn F, Bonnet N, Baruchet M, Sabatier M, Breton I, Bourqui B, et al. Galacto-
985 oligosaccharide preconditioning improves metabolic activity and engraftment of
986 *Limosilactobacillus reuteri* and stimulates osteoblastogenesis ex vivo. *Sci Rep.*
987 2024;14(4329):doi: 10.1038/s41598-024-54887-z.
- 988 21. Lucas S, Omata Y, Hofmann J, Bottcher M, Iljazovic A, Sarter K, et al. Short-chain
989 fatty acids regulate systemic bone mass and protect from pathological bone loss. *Nature*
990 *communications.* 2018;9(1):55.
- 991 22. Scholz-Ahrens KE, Adolphi B, Rochat F, Barclay DV, de Vrese M, Açil Y,
992 Schrezenmeir J. Effects of probiotics, prebiotics, and synbiotics on mineral metabolism in
993 ovariectomized rats - impact of bacterial mass, intestinal absorptive area and reduction of
994 bone turn-over. *NFS Journal.* 2016;3:41-50.
- 995 23. van den Heuvel E, Schoterman M, Muijs T. Trans-galactooligosaccharides stimulate
996 calcium absorption in postmenopausal women. *J Nutr* 2000;130:2938–42.
- 997 24. Leite ME, Lasekan J, Baggs G, Ribeiro T, Menezes-Filho J, Pontes M, et al. Calcium
998 and fat metabolic balance, and gastrointestinal tolerance in term infants fed milk-based
999 formulas with and without palm olein and palm kernel oils: a randomized blinded crossover
1000 study. *BMC Pediatr.* 2013;13(215):doi: 10.1186/471-2431-13-215.
- 1001 25. Nelson SE, Frantz JA, Ziegler EE. Absorption of fat and calcium by infants fed a milk-
1002 based formula containing palm olein. *J Am Coll Nutr.* 1998;17(4):327-32.
- 1003 26. Nelson SE, Rogers RR, Frantz JA, Ziegler EE. Palm olein in infant formula:
1004 absorption of fat and minerals by normal infants. *Am J Clin Nutr* 1996;64(3):291-6.
- 1005 27. Ostrom KM, Borschel MW, Westcott JE, Richardson KS, Krebs NF. Lower calcium
1006 absorption in infants fed casein hydrolysate- and soy protein-based infant formulas
1007 containing palm olein versus formulas without palm olein. *J Am Coll Nutr.* 2002;21(6):564-
1008 9.
- 1009 28. Nilsson A, Sundh D, Bäckhed F, Lorentzon M. *Lactobacillus reuteri* reduces bone
1010 loss in older women with low bone mineral density: a randomized, placebo-controlled,
1011 double-blind, clinical trial. *Journal of internal medicine.* 2018;284(3):307-17.
- 1012 29. Fiorotto ML, Davis TA. Critical Windows for the Programming Effects of Early-Life
1013 Nutrition on Skeletal Muscle Mass. *Nestle Nutr Inst Workshop Ser.* 2018;89:25-35.
- 1014 30. Orsso CE, Tibaes JRB, Oliveira CLP, Rubin DA, Field CJ, Heymsfield SB, et al. Low
1015 muscle mass and strength in pediatrics patients: Why should we care? *Clin Nutr*
1016 2019;38(5):2002-15.
- 1017 31. Fiorotto M. L, Davis T. A. Critical Windows for the Programming Effects of Early-Life
1018 Nutrition on Skeletal Muscle Mass. *Nestle Nutr Inst Workshop.* 2018;89:25-35.
- 1019 32. Bachman JF, J.V C. Insights into muscle stem cell dynamics during postnatal
1020 development. *FEBS J.* 2022;289(10):2710-22.
- 1021 33. Verdijk LB, Snijders T, Drost M, Delhaas T, Kadi F, van Loon LJ. Satellite cells in
1022 human skeletal muscle; from birth to old age. *Age.* 2014;36(2):545-7.
- 1023 34. Davis TA, Fiorotto ML, . Regulation of muscle growth in neonates. *Current opinion*
1024 *in clinical nutrition and metabolic care.* 2009;12(1):78-85.
- 1025 35. Giron M, Thomas M, Dardevet D, Chassard C, Savary-Auzeloux I. Gut microbes and
1026 muscle function: can probiotics make our muscles stronger? *J Cachexia Sarcopenia Muscle.*
1027 2022;13:1460-76.
- 1028 36. Chen HL, Lee WT, Lee PL, Liu PL, Yang RC. Postnatal Changes in Tibial Bone
1029 Speed of Sound of Preterm and Term Infants during Infancy. *PLoS One.*
1030 2016;11(11):e0166434.
- 1031 37. Soto Martinez ME, Love JC, Crowder CM, Wiersema JM, Pinto DC, Derrick SM, et
1032 al. The first step in an investigation of quantitative ultrasound as a technique for evaluating
1033 infant bone strength. *J Forensic Sci.* 2021;66(2):456-69.
- 1034 38. Wu Z, Yuan Y, Tian J, Long F, Luo W. The associations between serum trace
1035 elements and bone mineral density in children under 3 years of age. *Sci Rep.*
1036 2021;11(1):1890.
- 1037 39. Zadik Z, Price D, Diamond G. Pediatric reference curves for multi-site quantitative
1038 ultrasound and its modulators. *Osteoporos Int* 2003;14(10):857-62.


- 1039 40. Häger-Ross C, Rösblad B. Norms for grip strength in children aged 4-16 years. *Acta*
1040 *Paediatr* 2002;91(6):617-25.
- 1041 41. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA. A
1042 review of the measurement of grip strength in clinical and epidemiological studies: towards a
1043 standardised approach. *Age Ageing* 2011;40(4):423-9.
- 1044 42. Greenblatt MB, Tsai JN, Wein MN. Bone Turnover Markers in the Diagnosis and
1045 Monitoring of Metabolic Bone Disease. *Clin Chem*. 2017;63(2):464-74.
- 1046 43. Quinlan PT, Lockton S, Irwin J, Lucas AL. The relationship between stool hardness
1047 and stool composition in breast- and formula-fed infants. *J Pediatr Gastroenterol Nutr*.
1048 1995;20(1):81-90.
- 1049 44. Capeding MRZ, Phee LCM, Ming C, Noti M, Vidal K, Le Carrou G, et al. Safety,
1050 efficacy, and impact on gut microbial ecology of a *Bifidobacterium longum* subspecies
1051 *infantis* LMG11588 supplementation in healthy term infants: a randomized, double-blind,
1052 controlled trial in the Philippines. *Front Nutr* 2023;10:1319873.
- 1053 45. Nielsen HB, Almeida M, Juncker AS, Rasmussen S, Li J, Sunagawa S, et al.
1054 Identification and assembly of genomes and genetic elements in complex metagenomic
1055 samples without using reference genomes. *Nat Biotechnol* 2014;32(8):822-8.
- 1056 46. Langfelder P, Zhang B, Horvath S. Defining clusters from a hierarchical cluster tree:
1057 the Dynamic Tree Cut package for R. *Bioinformatics*. 2008;24(5):719-20.
- 1058 47. Aitchison J. The Statistical Analysis of Compositional Data. *Journal of the Royal*
1059 *Statistical Society*. 1982;44(2):139-77.
- 1060 48. Zhou H, He K, Chen J, Zhang X. LinDA: linear models for differential abundance
1061 analysis of microbiome compositional data. *Genome Biol*. 2022;23(1):95. doi: 10.1186.
- 1062 49. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and
1063 Powerful Approach to Multiple Testing Get access Arrow. *Journal of the Royal Statistical*
1064 *Society*.. 1995;57(1):289–300.
- 1065 50. Ancel S, Michaud J, Migliavacca E, Jomard C, Fessard A, Garcia P, et al. The
1066 combination of nicotinamide and pyridoxine stimulates muscle stem cell expansion and
1067 enhances regenerative capacity. *Journal clinical investigation*. 2024;Under review.
- 1068 51. Lui JC. Gut microbiota in regulation of childhood bone growth. *Exp Physiol*.
1069 2024;109(5):662-71.
- 1070 52. Bohannon RW, Wang YC, Bubela D, Gershon RC. Handgrip Strength: A Population-
1071 Based Study of Norms and Age Trajectories for 3- to 17-Year-Olds. *Pediatr Phys Ther*
1072 2017;29(2):118-23.
- 1073 53. Flores-Aldana M, Rivera-Pasquel M, García-Guerra A, Pérez-Cortés JG, Bárcena-
1074 Echegollén JE. Effect of Vitamin D Supplementation on (25(OH)D) Status in Children 12-30
1075 Months of Age: A Randomized Clinical Trial. *Nutrients*. 2023;15(12):2756. doi: 10.3390.
- 1076 54. Jones ML, Martoni CJ, Prakash S. Oral supplementation with probiotic *L. reuteri*
1077 NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a
1078 randomized controlled trial. *J Clin Endocrinol Metab*. 2013;98(7):2944-51.
- 1079 55. Havlicekova Z, Jesenak M, Banovcin P, Kuchta M. Beta-palmitate - a natural
1080 component of human milk in supplemental milk formulas. *Nutr J* 2016;15(28):doi: 10.1186.
- 1081 56. Depeint F, Tzortzis G, Vulevic J, I'anson K, Gibson GR. Prebiotic evaluation of a
1082 novel galactooligosaccharide mixture produced by the enzymatic activity of *Bifidobacterium*
1083 *bifidum* NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-
1084 controlled intervention study. *Am J Clin Nutr* 2008;87:785-91.
- 1085 57. Knysch O. V. Bifidogenic properties of cell-free extracts derived from probiotic strains
1086 of *Bifidobacterium bifidum* and




1087 *Lactobacillus reuteri*. *Regulatory Mechanisms in Biosystems*. 2019;10:124–8.
- 1088 58. Yu J, Cao G, Yuan S, Luo C, Yu J, Cai M. Probiotic supplements and bone health in
1089 postmenopausal women: a meta-analysis of randomised controlled trials. *BMJ Open*.
1090 2021;11(3):e041393.




- 1091 59. Prokopidis K, Giannos P, Reginster JY, Bruyere O, Petrovic M, Cherubini A, et al.
1092 Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a
1093 systematic review and meta-analysis. *J Cachexia Sarcopenia Muscle*. 2023;14(2):671-83.
1094 60. Du L, Qi R, Wang J, Liu Z, Wu Z. Indole-3-Propionic Acid, a Functional Metabolite of
1095 *Clostridium sporogenes*, Promotes Muscle Tissue Development and Reduces Muscle Cell
1096 Inflammation. *Int J Mol Sci* 2021;22(22):12435.
1097 61. Suzuki A, Iwata J. Amino acid metabolism and autophagy in skeletal development
1098 and homeostasis. *Bone*. 2021;146: doi: 10.1016/j.bone.2021.
1099 62. Michalowska M, Znorko B, Kaminski T, Oksztulska-Kolanek E, Pawlak D. New
1100 insights into tryptophan and its metabolites in the regulation of bone metabolism. *J Physiol*
1101 *Pharmacol*. 2015;66(6):779-91.
1102 63. Al Saedi A, Sharma S, Summers MA, Nurgali K, Duque G. The multiple faces of
1103 tryptophan in bone biology. *Exp Gerontol*. 2020;129:110778. doi: 10.1016.
1104 64. Jiang Q, Zhao Y, Zhou XQ, Wu XY, Xu SX, Feng L, et al. Effects of dietary
1105 tryptophan on muscle growth, protein synthesis and antioxidant capacity in hybrid catfish
1106 *Pelteobagrus vachelli* × *Leiocassis longirostris*. *Br J Nutr* 2022;127(12):1761-73.
1107 65. Jourdan M, Nair KS, Carter RE, Schimke J, Ford GC, Marc J, et al. Citrulline
1108 stimulates muscle protein synthesis in the post-absorptive state in healthy people fed a low-
1109 protein diet - A pilot study. *Clin Nutr*. 2015;34(3):449-56.
1110 66. Suzuki T, Morita M, Kobayashi Y, Kamimura A. Oral L-citrulline supplementation
1111 enhances cycling time trial performance in healthy trained men: Double-blind randomized
1112 placebo-controlled 2-way crossover study. *J Int Soc Sports Nutr* 2016;13(6):doi: 10.1186.
1113 67. Nauta S, Greven J, Hofman M, Mohren R, Meesters DM, Möckel D, et al. Mass
1114 Spectrometry Reveals Molecular Effects of Citrulline Supplementation during Bone Fracture
1115 Healing in a Rat Model. *J Am Soc Mass Spectrom*. 2024;35(6):1184-96.
1116 68. Dao HT, Moss AF, Bradbury EJ, Swick RA. Effects of L-arginine, guanidinoacetic
1117 acid and L-citrulline supplementation in reduced-protein diets on bone morphology and
1118 mineralization of laying hens. *Anim Nutr*. 2023;14(16):225-34.
1119 69. Zdzieblik D, Oesser S, Baumstark MW, Gollhofer A, König D. Collagen peptide
1120 supplementation in combination with resistance training improves body composition and
1121 increases muscle strength in elderly sarcopenic men: a randomised controlled trial. *Br J*
1122 *Nutr* 2015;114(8):1237-45.

1123

A**B****C****D****E****F****G****H****I****J**



A**B****C**

A**B****C****D**